The announcement that the FDA will review a second drug candidate from antibiotic specialist Cubist Pharmaceuticals ($CBST), speculation is ramping up that it is ripe for a takeover. Pfizer ($PFE), which has a competing drug for which Cubist hopes to get FDA approval, is one possible suitor being mentioned. Johnson & Johnson ($JNJ) and Eli Lilly ($LLY) are also mentioned as having the cash and competency to make a run at Cubist. Report | More